HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia

References

• Newell LF, Cook RJ. Advances in acute myeloid leukemia. Br Med J. 2021;375:n2026. doi:10.1136/bmj.n2026.
   PubMedGoogle Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra1406184.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27. doi:10.6004/jnccn.2021.0002
   PubMed Web of Science ®Google Scholar
• Hu KX, Du X, Guo M, et al. Comparative study of micro-transplantation from HLA fully mismatched unrelated and partly matched related donors in acute myeloid leukemia. Am J Hematol. 2020;95(6):630–636. doi:10.1002/ajh.25780
   PubMed Web of Science ®Google Scholar
• David KA, Cooper D, Strair R. Clinical studies in hematologic microtransplantation. Curr Hematol Malig Rep. 2017;12(1):51–60. doi:10.1007/s11899-017-0361-6
   PubMed Web of Science ®Google Scholar
• Leonard JP, Martin P, Roboz GJ. Practical implications of the 2016 revision of the world health organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol. 2017;35(23):2708–2715. doi:10.1200/JCO.2017.72.6745
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi:10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• Li X, Dong Y, Li Y, et al. Egfr and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma. BMC Cancer. 2019;79(1):819. doi:10.1158/0008-5472.CAN-18-1273
   Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Derman BA, Larson RA. Post-remission therapy in acute myeloid leukemia: are we ready for an individualized approach? Best Pract Res Clin Haematol. 2019;32(4):101102. doi:10.1016/j.beha.2019.101102
   PubMed Web of Science ®Google Scholar
• Guo M, Hu KX, Liu GX, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol. 2012;30(33):4084–4090. doi:10.1200/JCO.2012.42.0281
   PubMed Web of Science ®Google Scholar
• Kolla BC, Halim NAA, Cao Q, et al. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. Br J Haematol. 2021;194(1):140–144. doi:10.1111/bjh.17462
   PubMed Web of Science ®Google Scholar
• Kolonen A, Sinisalo M, Huhtala H, et al. Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group. Eur J Haematol. 2022;109(3):257–270. doi:10.1111/ejh.13805
   PubMed Web of Science ®Google Scholar
• Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 cancer and leukemia group B study (CALGB 10503). Leukemia. 2017;31(1):34–39. doi:10.1038/leu.2016.252
   PubMed Web of Science ®Google Scholar
• Guo Y, Deng L, Qiao Y, et al. Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma. Hematology. 2022;27(1):1272–1281. doi:10.1080/16078454.2022.2150389
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/JCO.2017.77.6112
   PubMed Web of Science ®Google Scholar
• Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457–1464. doi:10.1182/blood-2018-10-879866
   PubMed Web of Science ®Google Scholar
• Cerchione C, Romano A, Daver N, et al. Mechanisms of action of the new antibodies in use in multiple myeloma. Front Oncol. 2021;11:639387. doi:10.3389/fonc.2021.684561
   PubMedGoogle Scholar
• Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208–217. doi:10.1002/ajh.26039
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Chen J, Yang L, Fan Y, et al. Comparison of autologous stem cell transplantation versus haploidentical donor stem cell transplantation for favorable- and intermediate-risk acute myeloid leukemia patients in first complete remission. Biol Blood Marrow Transplant. 2018;24(4):779–788. doi:10.1016/j.bbmt.2017.12.796
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen X, Feng S. Autologous stem cell transplantation for multiple myeloma: growth factor matters. Biol Blood Marrow Transplant. 2019;25(9):e293–e297. doi:10.1016/j.bbmt.2019.05.035
   PubMedGoogle Scholar
• Li Z, Liu Y, Wang Q, et al. Autologous stem cell transplantation is a viable postremission therapy for intermediate-risk acute myeloid leukemia in first complete remission in the absence of a matched identical sibling: a meta-analysis. Acta Haematol. 2019;141(3):164–175. doi:10.1159/000495206
   PubMed Web of Science ®Google Scholar
• Guo M, Chao NJ, Li JY, et al. HLA-Mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia. JAMA Oncol. 2018;4(1):54–62. doi:10.1001/jamaoncol.2017.2656
   PubMed Web of Science ®Google Scholar
• Pan B, Lazarus HM, Gale RP. Microtransplantation for acute myeloid leukemia. JAMA Oncol. 2020;6(10):1614–1620. doi:10.1001/jamaoncol.2020.1706
   PubMed Web of Science ®Google Scholar
• Sung AD, Jauhari S, Siamakpour-Reihani S, et al. Microtransplantation in older patients with AML: a pilot study of safety, efficacy and immunologic effects. Am J Hematol. 2020;95(6):662–671. doi:10.1002/ajh.25781
   PubMed Web of Science ®Google Scholar
• Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011;117(3):936–941. doi:10.1182/blood-2010-06-288506
   PubMed Web of Science ®Google Scholar
• Fathi AT, Hobbs G, Dey BR, et al. Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia. Am J Hematol. 2018;93(10):E331–E333. doi:10.1002/ajh.25218
   PubMed Web of Science ®Google Scholar
• Punwani N, Merin N, Mohrbacher A, et al. Unrelated HLA mismatched microtransplantation in a patient with refractory secondary acute myeloid leukemia. Leuk Res Rep. 2018;9:18–20. doi:10.1016/j.lrr.2018.02.002
   PubMedGoogle Scholar
• Liu L, Zhang X, Qiu H, et al. HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/high-risk acute myeloid leukemia. Ann Hematol. 2019;98(5):1249–1257. doi:10.1007/s00277-018-3583-3
   PubMed Web of Science ®Google Scholar
• Rubio MT, Zhao G, Buchli J, et al. Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning. Clin Immunol. 2006;120(1):33–44. doi:10.1016/j.clim.2006.03.004
   PubMed Web of Science ®Google Scholar
• Symons HJ, Levy MY, Wang J, et al. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008;14(5):499–509. doi:10.1016/j.bbmt.2008.02.013
   PubMed Web of Science ®Google Scholar
• Colvin GA, Berz D, Ramanathan M, et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant. 2009;15(4):421–431. doi:10.1016/j.bbmt.2008.12.503
   PubMed Web of Science ®Google Scholar
• Krakow EF, Bergeron J, Lachance S, et al. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Rev. 2014;28(6):249–261. doi:10.1016/j.blre.2014.08.002
   PubMed Web of Science ®Google Scholar
• Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, et al. Long-Term outcomes after autologous versus allogeneic stem cell transplantation in molecularly-stratified patients with intermediate cytogenetic risk acute myeloid leukemia: a PETHEMA study. Transplant Cell Ther. 2021;27(4):311.e1–311.e10. doi:10.1159/000495206
   PubMedGoogle Scholar
• Borlenghi E, Cattaneo C, Cerqui E, et al. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. Hematol Oncol. 2020;38(5):754–762. doi:10.1002/hon.2806
   PubMed Web of Science ®Google Scholar